IL139736A - Process for preparing crystalline alkali metal salt of amoxycillin - Google Patents

Process for preparing crystalline alkali metal salt of amoxycillin

Info

Publication number
IL139736A
IL139736A IL13973699A IL13973699A IL139736A IL 139736 A IL139736 A IL 139736A IL 13973699 A IL13973699 A IL 13973699A IL 13973699 A IL13973699 A IL 13973699A IL 139736 A IL139736 A IL 139736A
Authority
IL
Israel
Prior art keywords
amoxycillin
process according
salt
solution
sodium
Prior art date
Application number
IL13973699A
Other languages
Hebrew (he)
Other versions
IL139736A0 (en
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL139736A0 publication Critical patent/IL139736A0/en
Publication of IL139736A publication Critical patent/IL139736A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/04Preparation
    • C07D499/14Preparation of salts
    • C07D499/16Preparation of salts of alkali or alkaline earth metals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Description

12204/00 139736/2 PROCESS FOR PREPARING CRYSTALLINE ALKALI METAL SALT OF AMOXYCILLIN / PROCESS FOR PREPARING CRYSTALLINE SALTS OF AMOXYCILLIN This invention relates to a process for the preparation of crystalline salts of the beta lactam antibiotic amoxycillin viz. 6-[Iaroino {^hydroxypben acet ll-aminoJ-S.S-dtrnethyl-7-oxo-4-thia-l-a2abtcyclo [3.2,0] heptane- 2-carboxylic acid. In particular this invention relates to a process for the preparation of crystalline sodiuin amoxycillin.
Crystalline sodium amoxycillin is a known substance and processes for its preparation are disclosed in the state of the art. For example EP 0131147A discloses a process in which amoxycillin trihydrate is converted into a crystalline solvate of sodium amoxycillin from which the solvating solvent is removed. In one experimental example of this disclosure amoxycillin trihydrate is suspended hi methyl acetate, then a solution of a mixture of triethylamine and sodium 2-ethylhexanoate is added to this suspension. In EP 0596262A amoxycillin trihydrate is dissolved in a methyl acetate / isoprapanol / triethylamine mixture, then this solution is added to a solution of sodium 2-ethylhexanoate in a methyl acetate / methanol mixture. A crystalline solvate of sodium amoxycillin is believed to crystallize out from the reaction mixture, from which the solvating solvent is removed. In WO 97/15579 amoxycillin trihydrate is added to an ethanol / triethylamine mixture to form a solution which is then reacted with sodium 2-ethylhexanoate in ethanolic solution, and a crystalline product is obtained. In US 4737585 amoxycillin trihydrate is suspended in a mixture of an aprotic solvent, such as methylene chloride, and a lower alcohol, the amoxycillin is solubilized using a low molecular weight amine, and to this mixture is added the sodium salt of diethytoxalacetk acid. Sodium amoxycillin is then precipitated by addition of more of the aprotic solvent.
In processes used to prepare crystalline sodium amoxycillin it is desirable to minimize the quantities of solvents used and to improve yield and purity of the product. Consequently there is an ongoing problem of process improvement. It is an object of the present invention to provide an alternative and improved process for the preparation of crystalline sodium amoxycillin. Other objects and advantages of the present invention will be apparent from the following description.
According to this invention a process for the preparation of a crystalline alkali metal salt of amoxycillin is provided, in which; a suspension of an amine salt of amoxycillin is formed in a first organic solvent. the suspension is admixed with a second organic solvent and the amine salt is caused to enter solution in the so-formed mixture of first and second organic solvents, the amine salt is reacted with a salifying compound of the alkali metal, the so-formed alkali metal salt of amoxycillin is isolated from the solution as a crystalline product.
In the process of the invention it is believed that the formation of the suspension of the amine salt in the first solvent, and rapid dissolution of the salt when the second organic solvent 1-5 is admixed, leads to decreased breakdown of the amoxycillin, and consequently increased yield and purity of the crystalline product. In the process of this invention the reagents are formed into solution, which facilitates sterilising filtration and consequent use of the product as an injectible pharmaceutical product. However the process of the present invention may equally effectively be used without a sterile filtration step to prepare crystalline sodium amoxycillin which may be administered orally.
Preferably the crystalline alkali metal salt of amoxycillin prepared by the process of this invention is crystalline sodium amoxycillin.
Preferably the amine salt of amoxycillin is a salt of a tri- or di- (Cl-5)alkyl amine, such as triethylamine, diethylamine or diisopropylamine, especially the triethylamine, salt of amoxycillin. A mixture of amine salts may be used such as a mixture of the salts of amoxycillin with triethylamine and diisopropylamine. Other suitable amine salts include the salt with dicyclohexylamine.
A preferred first organic solvent is a (Cl-5)alkyl (Cl-5)alkanoate ester, a preferred such ester being a (Cl-5 )alkyl acetate ester, particularly methyl acetate. The first organic solvent may comprise a single solvent or a mixture of solvents, for example a mixture of said esters or said esters and other co-solvents.
Preferably the suspension is formed by first forming a suspension of amoxycillin, preferably in the form of amoxycillin trihydrate, in the first organic solvent then admixing the amine with this suspension so that the amine reacts with the amoxycillin to form the amine salt. This reaction is preferably carried out at below ambient temperature, for example below 10°C, especially at 0-5°C. Suitably the amoxycillin trihydrate may be suspended in a volume of methyl acetate at a ratio weight of amoxycillin trihydrate : volume of methyl acetate ca. 1 : 1 - 1 :2.5, for example typically 1 :1.7 - 1: 2, and this suspension may be admixed with the triethylamine in a stoichiometric excess to the amoxycillin, for example at a molar ratio amoxycillin : triethylamine 1:1 - 1:2, for example typically 1:1.3 - 1:1.5.
A suitable second organic solvent with which the suspension of the amine salt may be admixed is a (CI -5)alcohol, such as methyl alcohol, which is preferred, or ethyl alcohol, propyl alcohol e.g. isopropyl alcohol, or butyl alcohol e.g. iso-butyl alcohol. The second organic solvent may comprise a single solvent or a mixture of solvents, for example a mixture of said alcohols or said alcohols and other co-solvents.
The admixing of the second solvent and the suspension of the amine salt in the first solvent causes the salt to enter solution, and the volume of the second solvent e.g. the alcohol used may be determined experimentally as the minimum volume of the second solvent necessary to achieve this. Typically when the first solvent is the above-described ester and the second solvent is the above-described alcohol a volume ratio ester : alcohol of ca. 1: 0.3 - 0.6 will be found suitable, e.g. about 1 : 0.4-0.5 of methyl acetate : methyl alcohol. If such a volume ratio of methyl alcohol is admixed with the above-described suspension of the triethyiamine salt of amoxycillin then the salt generally dissolves immediately upon stirring.
At this stage the so-formed solution of the amine salt of amoxycillin may for example be filtered and or treated by other standard purification steps e.g. treatment with dicalite or other materials which selectively absorb impurities. If the solution is filtered the filter medium may subsequently be washed with more of the second solvent e.g. the alcohol, e.g. corresponding to an amount 0.5 - 1.0 of the amount already in admixture with the solution of the salt.
A suitable salifying compound is a pharmaceutically acceptable salifying compound of a suitable alkali metal, for example the sodium salt of an organic compound, for example an alcoholate such as of a (CI -5)alcohol e.g. the methoxide and/or ethoxide, or a salt of an organic acid e.g. a (CI- 12) carboxylic acid such as an alkyl substituted- alkanoate for example a 2-ethylhexanoate. In the case of preparation of crystalline sodium amoxycillin sodium 2-ethylhexanoate is a preferred salifying compound.
The reaction of the amine salt is suitably carried out by admixing the solution of the amine salt with a solution of the salifying compound. Suitably the salifying compound is in solution in a solvent mixture which comprises the abovementioned first and second organic solvents, e.g. the abovementioned (Cl-5 )alkyl (C l-5)alkanoate ester and (CI -5)alcohol, for example a methyl acetate : methanol mixture comprising predominantly the ester, for example a 9- 12 : 1 v:v, e.g. 10-11 : 1 v:v methyl acetate : methanol mixture. Suitably a stoichiometric excess of the salifying compound relative to the amoxycillin is used, e.g. a 1.5 - 2.5 : 1 molar ratio of sodium 2-ethyl hexanoa e : amoxycillin. Suitably a solution of sodium 2-ethyihexanoate in the abovementioned solvent mixture which is of concentration around 1.8 - 2.5 M may be used. This solution may be filtered and/or subjected to other appropriate purification steps before the reaction with the amoxycillin.
Preferably the reaction between the salifying compound and the amoxycillin is carried out at below ambient temperature, e.g. below 10°C, especially at 0-5°C. Preferably the solution of the amine salt is added to the solution of the salifying compound, although the reverse mode of addition, i.e. addition of the solution of the salifying compound to the solution of the amine salt, or concurrent admixing, may be used. Preferably the mixing of the two solutions is carried out as fast as possible, with rapid stirring.
Spontaneous crystallization of the reaction product may occur, but it is preferred to induce crystallization by the addition of seed crystals, e.g. of crystalline sodium amoxycillin or some crystallographically equivalent material e.g. a solvate of crystalline sodium amoxycillin, to the reaction mixture immediately after the mixing of the solutions. To further encourage crystallization further of the abovementioned first organic solvent e.g. the (Cl-5)alkyl (Cl -5)alkanoate ester, e.g. methyl acetate, may be admixed with the reaction mixture, preferably in excess of the reaction medium volume e.g. in a 1.5 - 2.0 x excess of the reaction medium volume. This admixing of the first organic solvent may be carried out relatively slowly, e.g. over a period of ca. 30-40 minutes. After the admixing of this further amount of the first solvent the mixture may be stirred for a time, e.g. ca. 1 hour preferably below ambient temperature, e.g. below 10°C, especially at 0-5°C.
After this stage the crystalline product may be separated off from the reaction medium using standard procedures, e.g. filtered off, and washed with a suitable wash liquid, preferably the first organic solvent.
The crystalline product obtained in this way is believed to be a crystalline solvate of sodium amoxycillin, e.g. the methyl acetate solvate from which the solvating solvent may be removed by a drying process, e.g. the process disclosed in EP 0131 147 A, the contents of which are incorporated herein by reference. This drying process may be in vacuum preferably at an elevated temperature such as 50-65°C, for example 60-65°C to remove residual reaction medium solvents, wash liquids and solvating solvents, to yield the crystalline alkali metal salt of amoxycillin.
Crystalline sodium amoxycillin prepared by the process of this invention may be used as a pharmaceutical antibiotic product e.g. in injectible form. For this purpose it may be provided contained in sealed sterile vials. Alternatively the sodium amoxycillin prepared by the process of this invention may be used in formulations for oral administration e.g. in tablet, granule, syrup etc formulations and for oral administration sterile formulation is not necessarily required. Preferably for use as an antibiotic product the product crystalline alkali metal salt of amoxycillin is administered in combination with a pharmaceutically acceptable beta-lactamase inhibitor such as a salt of clavulanic acid, particularly potassium clavulanate.
The invention will now be illustrated by way of non-limiting example.
Example 1 : Laboratory Scale. .1 Dissolution of sodium 2-ethyl hexanoate.
Sodium 2-ethyl hexanoate (160g) was dissolved in a mixture of methyl acetate (310ml) and methanol (30ml). The mixture was stirred at room temperature until dissolution was complete and the solution was filtered through Whatman No. 1 filter paper to remove cloudiness. The solution was transferred to a crystallization vessel, followed by a wash of methyl acetate (210ml) and stirred at 0-5°C. This solution was consequently 2.15M in Sodium 2-ethyl hexanoate. 1.2 Dissolution of amoxycillin trihydrate.
Amoxycillin trihydrate (250g) was slurried in methyl acetate (450ml).
Triethylamine (120 ml) was added to the slurry creating a thick suspension. Methanol (200ml) was added, causing the amoxycillin triethylamine salt to dissolve instantly. The solution was stirred for 5 minutes before dicalite (lOg) was added and the mixture was allowed to stir for a further 5 minutes. The solution was then filtered through Whatman No. 1 filter paper followed by a wash with methanol (120ml) and transferred to the crystallization vessel containing sodium 2-ethyl hexanoate from 1.1 above. 1.3 Reaction and crystallization.
The mixture in the crystallization vessel was stirred vigorously at 0-S°C and crystalline sodium amoxycillin seed (lg) was added. As crystallization began methyl acetate (2300ml) was added over a period of 30-40 minutes. The mixture was allowed to stir for 1 hour at 0-5°C. The product was then filtered and washed with methyl acetate (750ml). 1.4 Drying The crystalline product from 1.3 was dried under vacuum at 50-55°C for 36 hours, or alternatively at 65°C for the shorter period of 16 hours. Product quality was found to be unaffected by the drying temperature. The product was confirmed to be crystalline sodium amoxycillin by chemical analysis, infrared spectroscopy and X-ray powder diffractometry.
The product obtained had an amoxycillin content of 1.0%, with a total content of impurities of 2.13 - 2.16%.
Example 2: Scale up. 2.1 Dissolution of sodium 2-ethyl hexanoate.
Methyl acetate (124L) was added to sodium 2-ethyl hexanoate (64kg), and methanol (12L) was added with stirring until the sodium 2-ethyl hexanoate dissolved. The solution was filtered and transferred to a crystallization vessel, washing in with methyl acetate (84L). 2.2 Dissolution of amoxycillin trihydrate.
Methyl acetate (124L) was added to amoxycillin trihydrate (87.1kg) and the resulting suspension was cooled to 0-5°C. Triethylamine (48.1L) was added to the slurry and the slurry was stirred for 5 minutes. Methanol (80L) was added causing the amoxycillin triethylamine salt to dissolve and the solution was stirred for S minutes. Dicalite (2kg) was added and the mixture was stirred for a further 5 minutes. The solution was then filtered and the cake was washed through with methanol (48L). 2.3 Reaction and crystallization.
The solution of amoxycillin triethylamine salt from 2.2 was added to the sodium 2-ethyl hexanoate solution from 2.1 as fast as possible and the mixture was cooled to 0-5°C. Crystalline sodium amoxycillin seed (400g) was added. Methyl acetate (921L) was added at a rate of 27 litres per minute. The mixture was stirred for 1 hour at 0-5°C. The slurry was then transferred to a Nutrex™ mixer and the mother liquor was filtered. The product was then washed with methyl acetate (84L). 2.4 Drying The crystalline product from 2.3 was blow dried with nitrogen, and then dried in vacuum at 60-65°C.
The product obtained had an amoxycillin content of 89.7 - 93.6%, with a total content of impurities of 1.72 - 1.42% over three batches.

Claims (16)

139736/2 Claims:
1. A process for the preparation of a crystalline alkali metal salt of amoxycillin is provided, in which; a suspension of an amine salt of amoxycillin is formed in a first organic solvent, the suspension is admixed with a second organic solvent and the amine salt is caused to enter solution in the so-formed mixture of first and second organic solvents, the amine salt is reacted with a salifying compound of the alkali metal, the so-formed alkali metal salt of amoxycillin is isolated from the solution as a crystalline product.
2. A process according to claim 1 wherein the crystalline alkali metal salt of amoxycillin prepared by the process is crystalline sodium amoxycillin.
3. A process according to claim 1 wherein the amine salt of amoxycillin is a triethylamine, diethylamine or diisopropylamine salt of amoxycillin.
4. A process according to claim 1 wherein the first organic solvent is a (C l-5)alkyl (Cl-5)alkanoate ester
5. A process according to claim 4 wherein the (C 1-5) alkyl (C l-5)alkanoate ester is methyl acetate.
6. A process according to claim 1 wherein the suspension of the amine salt is formed by first forming a suspension of amoxycillin trihydrate in the first solvent then admixing the amine with this suspension so that the amine reacts with the amoxycillin to form the amine salt.
7. A process according to claim 1 wherein the second organic solvent is a (C 1-5) alcohol.
8. A process according to claim 7 wherein the (C l-5)alcohol is methyl alcohol.
9. A process according to claim 1 wherein the salifying compound is a sodium salt of an organic compound.
10. A process according to claim 9 wherein the salifying compound is a sodium salt of a (Cl-5)alcohol or a salt of a (C 1-12) carboxylic acid.
11. 1 1. A process according to claim 8 wherein the salifying compound is sodium 2-ethylhexanoate.
12. A process according to claim 1 wherein the reaction of the amine salt is carried out by admixing the solution of the amine salt with a solution of the salifying compound.
13. A process according to claim 10 wherein the salifying compound is in solution in a solvent mixture which comprises the first and second organic solvents.
14. A process according to claim 13 wherein the solvent mixture is a methyl acetate : methanol mixture comprising predominantly methyl acetate.
15. A process according to claim 12 wherein the solution of the amine salt is added to the solution of the salifying compound.
16. A crystalline alkali metal salt of amoxycillin being the product of a process according to Claim 1.
IL13973699A 1998-06-01 1999-06-01 Process for preparing crystalline alkali metal salt of amoxycillin IL139736A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8755498P 1998-06-01 1998-06-01
PCT/US1999/011991 WO1999062910A1 (en) 1998-06-01 1999-06-01 Process for preparing crystalline salts of amoxycillin

Publications (2)

Publication Number Publication Date
IL139736A0 IL139736A0 (en) 2002-02-10
IL139736A true IL139736A (en) 2004-02-19

Family

ID=22205864

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13973699A IL139736A (en) 1998-06-01 1999-06-01 Process for preparing crystalline alkali metal salt of amoxycillin

Country Status (15)

Country Link
EP (1) EP1086109A4 (en)
JP (1) JP2002517398A (en)
KR (1) KR20010043942A (en)
CN (1) CN1182138C (en)
AU (1) AU760934B2 (en)
BR (1) BR9910804A (en)
CA (1) CA2333943A1 (en)
HU (1) HUP0102008A3 (en)
IL (1) IL139736A (en)
NO (1) NO20006073D0 (en)
NZ (1) NZ508179A (en)
PL (1) PL344348A1 (en)
TR (1) TR200003517T2 (en)
WO (1) WO1999062910A1 (en)
ZA (1) ZA200006946B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
WO2006072577A1 (en) * 2005-01-07 2006-07-13 Sandoz Ag Process for preparing granulates comprising amoxicillin
CN101633663B (en) * 2009-08-28 2011-12-21 沈阳顺旺动物药业有限公司 Method for synthesizing penicillin sodium salt and potassium salt
EP2582708A4 (en) * 2010-06-16 2014-01-15 Vardhman Chemtech Ltd Improved process for preparing amoxicillin sodium

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8606871A1 (en) * 1985-10-21 1986-06-01 Antibioticos Sa A process for the preparation of sodium amoxycillin.
IT1255716B (en) * 1992-10-05 1995-11-10 PROCEDURE FOR THE PREPARATION OF STERILE BETA-LACTAMIC ANTIBIOTICS
TW347383B (en) * 1995-10-26 1998-12-11 Biochemie Gmbh A process for the production of a crystalline sodium salt of amoxicillin in ethanol as solvent

Also Published As

Publication number Publication date
ZA200006946B (en) 2002-01-28
HUP0102008A3 (en) 2002-07-29
CA2333943A1 (en) 1999-12-09
HUP0102008A2 (en) 2001-12-28
IL139736A0 (en) 2002-02-10
NO20006073L (en) 2000-11-30
EP1086109A4 (en) 2001-12-19
NO20006073D0 (en) 2000-11-30
AU4321699A (en) 1999-12-20
KR20010043942A (en) 2001-05-25
NZ508179A (en) 2002-10-25
BR9910804A (en) 2001-02-13
PL344348A1 (en) 2001-11-05
WO1999062910A1 (en) 1999-12-09
JP2002517398A (en) 2002-06-18
TR200003517T2 (en) 2001-06-21
AU760934B2 (en) 2003-05-22
EP1086109A1 (en) 2001-03-28
CN1304412A (en) 2001-07-18
CN1182138C (en) 2004-12-29

Similar Documents

Publication Publication Date Title
MXPA03003312A (en) Pharmaceutical compositions.
JPH02191255A (en) Preparation of stable modification of
AU760934B2 (en) Process for preparing crystalline salts of amoxycillin
US20020137926A1 (en) Process for preparing crystalline salts of amoxycillin
AU607136B2 (en) Beta-lactam antibiotics
JPH089630B2 (en) Improvement of or related to organic compounds
US7767823B2 (en) Process for the purification of a salt of clavulanic acid
AU702968B2 (en) Clavulanic acid salts
US6103897A (en) Production of a crystalline salt of amoxicillin
MXPA00011833A (en) Process for preparing crystalline salts of amoxycillin
US11124526B2 (en) Crystalline beta-lactamase inhibitor
US7550593B2 (en) Process for the preparation of finasteride Form I
EP0039967B1 (en) Solvate of amoxicillin, process for the preparation thereof and process for the preparation of injectable preparations from this solvate
CZ20004445A3 (en) Process for preparing crystalline salts of amoxycillin
EP0101170B1 (en) Process for the manufacture of sodium cefoperazone
EP0004740B1 (en) A penicillin salt, process for its preparation and pharmaceutical compositions containing it
KR0169534B1 (en) Process for preparing high density and high crystalline cefoperazone sodium
RU2272041C1 (en) Method for isolating oxacillin sodium salt from aqueous and aqueous-organic media
KR100512870B1 (en) Method for producing 7α-methoxycephalosporin derivative sodium salt 7-hydrate
JPH0720971B2 (en) Crystalline amoxicillin sodium, process for producing the same, and pharmaceutical composition containing the same
SK284307B6 (en) Process for the preparation of easily separable crystalline benzatin salt of phenoxymethyl penicillin
IE48096B1 (en) A penicillin salt,process for its preparation and pharmaceutical compositions containing it
MXPA97004693A (en) Clavulan acid salts

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees